SMARCA4 mutation was associated with sensitivity to four FLT1 (VEGFR1) inhibitors in ovarian cancer cells, including axitinib, foretinib, pazopanib and sorafenib (Additional file 1: Fig. S11). Here, SMARCA4 is linked to ovarian carcinoma.